
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc is focused on developing innovative gene therapies for neurodegenerative diseases, and recent modifications to the trial protocol for PBFT02 may enable earlier intervention, potentially leading to enhanced patient outcomes. The company's valuation suggests room for growth, particularly if it secures regulatory alignment for accelerated approval based on biomarker endpoints, which could shorten trial durations and enhance the speed of bringing therapies to market. Additionally, the faster enrollment strategy in Cohort 3 could expedite trial progress, positioning Passage Bio favorably in a competitive landscape for genetic medicines targeting these critical conditions.
Bears say
Passage Bio Inc faces significant challenges that contribute to a negative outlook on its stock. The company's early-stage gene therapy programs are susceptible to delays and safety concerns, particularly surrounding immune reactions, which could adversely affect market sentiment and lead to downward revisions of estimates. Furthermore, the complexities associated with manufacturing AAV-based gene therapy products pose an additional risk, as insufficient production capabilities could constrain the company's forecasts and hinder its development timelines.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares